• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Minerva Surgical Inc. (Amendment)

    11/3/22 4:07:59 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology
    Get the next $UTRS alert in real time by email
    SC 13G/A 1 d418933dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Minerva Surgical, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    60343F 106

    (CUSIP Number)

    October 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: 60343F 106

     

      1.    

      Name of Reporting Person:

     

      Novo Holdings A/S

      2.  

      Check the Appropriate Box if a Member of Group (See Instructions):

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only:

     

      4.  

      Citizenship or Place of Organization:

     

      Denmark

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power:

     

      1,322,473

       6.  

      Shared Voting Power:

     

      0

       7.  

      Sole Dispositive Power:

     

      1,322,473

       8.  

      Shared Dispositive Power:

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      1,322,473

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares:

     

      ☐

    11.  

      Percent of Class Represented By Amount In Row (9):

     

      4.5% (1)

    12.  

      Type of Reporting Person:

     

      CO

     

    (1)

    Based upon 28,859,990 shares of the Issuer’s Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2022.

     

    2


    This Amendment No. 1 amends the Schedule 13G filed with the SEC on October 27, 2021 to report and reflect that Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Common Stock.

     

    Item 1. (a)

    Name of Issuer:

     

          

    Minerva Surgical, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

     

          

    4255 Burton Dr.

          

    Santa Clara, CA 95054

     

    Item 2. (a)

    Name of Person Filing:

     

          

    Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

     

      (b)

    Address or Principal Business Office or, if none, Residence:

     

          

    Tuborg Havnevej 19

          

    2900 Hellerup, Denmark

     

      (c)

    Citizenship or Place of Organization:

     

          

    Denmark

     

      (d)

    Title of Class of Securities:

     

          

    Common Stock

     

      (e)

    CUSIP Number:

     

          

    60343F 106

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    3


    Item 4.

    Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)   Amount beneficially owned:

         1,322,473 (1) 

    (b)   Percent of class:

         4.5 %(2) 

    (c)   Number of shares as to which such person has:

      

    (i) Sole power to vote or to direct the vote:

         1,322,473 (1) 

    (ii)  Shared power to vote or to direct the vote:

         0  

    (iii)  Sole power to dispose or to direct the disposition of:

         1,322,473 (1) 

    (iv) Shared power to dispose or to direct the disposition of:

         0  

     

    (1)

    Novo Holdings A/S has the sole power to vote and dispose of the shares, and no individual or other entity is deemed to hold any beneficial ownership in the shares.

    (2)

    Based upon 28,859,990 shares of the Issuer’s Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s 10-Q filed with the SEC on August 9, 2022.

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☒.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group:

    Not applicable.

     

    Item 10.

    Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 3, 2022     Novo Holdings A/S
       

    /s/ Barbara Fiorini Due

        By:   Barbara Fiorini Due
        Its:   General Counsel, Finance & Operations
    Get the next $UTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UTRS

    DatePrice TargetRatingAnalyst
    3/9/2022$17.00 → $12.00Overweight
    Piper Sandler
    12/3/2021$17.00 → $12.00Outperform
    SVB Leerink
    11/16/2021$17.00Outperform
    SVB Leerink
    11/16/2021$15.00Buy
    UBS
    11/16/2021$14.00Overweight
    JP Morgan
    11/16/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $UTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Minerva Surgical with a new price target

      Piper Sandler reiterated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

      3/9/22 6:38:44 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SVB Leerink reiterated coverage on Minerva Surgical with a new price target

      SVB Leerink reiterated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $12.00 from $17.00 previously

      12/3/21 9:34:35 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SVB Leerink initiated coverage on Minerva Surgical with a new price target

      SVB Leerink initiated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $17.00

      11/16/21 7:59:25 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      9/28/23 4:43:42 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      7/6/23 8:21:56 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      7/6/23 5:19:24 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $UTRS
    Financials

    Live finance-specific insights

    See more

    $UTRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 3: New insider Cohen Daniel claimed ownership of 122,189,638 shares

      3 - MINERVA SURGICAL INC (0001452965) (Issuer)

      3/14/23 5:37:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4: New Enterprise Associates 13 Lp bought $5,000,000 worth of shares (24,437,927 units at $0.20)

      4 - MINERVA SURGICAL INC (0001452965) (Issuer)

      2/10/23 9:25:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 3: New insider Accelmed Partners Ii L.P. claimed ownership of 122,189,638 shares

      3 - MINERVA SURGICAL INC (0001452965) (Issuer)

      2/9/23 4:28:55 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports Second Quarter 2023 Financial Results

      SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

      8/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports First Quarter 2023 Financial Results

      SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

      5/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical to Announce First Quarter 2023 Financial Results

      SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pe

      4/18/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports Third Quarter 2023 Financial Results

      SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023. Third Quarter Highlights: Reported revenue of $12.0 million in the third quarter of 2023, compared with revenue of $12.6 million in the third quarter of 2022Increased Symphion product revenue by 19% compared to the third quarter of 2022 "As we head into the fourth quarter of 2023, I am very pleased with the progress we have made to date in expanding the reach of our Sym

      11/13/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports Second Quarter 2023 Financial Results

      SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

      8/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports First Quarter 2023 Financial Results

      SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

      5/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Minerva Surgical Inc.

      15-12G - MINERVA SURGICAL INC (0001452965) (Filer)

      1/4/24 4:32:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 25 filed by Minerva Surgical Inc.

      25 - MINERVA SURGICAL INC (0001452965) (Filer)

      12/26/23 4:30:25 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form S-8 POS filed by Minerva Surgical Inc.

      S-8 POS - MINERVA SURGICAL INC (0001452965) (Filer)

      12/26/23 12:05:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer

      SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions. "We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity, while delivering bottom line results," said Todd Usen, president and CEO of Minerva Surgical. "Beyond her pro

      3/21/23 4:05:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO

      SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment an

      12/28/22 6:00:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of Directors

      SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) ("Minerva Surgical" or the "Company"), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced that the board of directors (the "Board") of Minerva Surgical has appointed Derrick Sung, Ph.D. to serve as a Class II director, with a term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified. The Board has affirmatively determined that Dr. Sung is an independent director pursuant to the listing standards of The NASDAQ Stock Market. "We are excited to have Derrick Sung, Ph.D. join the Board of Directo

      7/21/22 8:00:00 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology